Business Context and Reporting Period
This Form 8-K filing by Vanda Pharmaceuticals Inc. covers the date of January 18, 2012. The report addresses corporate governance changes specifically regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Resignation: Argeris N. Karabelas, Ph.D., resigned as a member of the Board of Directors, Chairman of the Compensation Committee, and member of the Nominating/Corporate Governance Committee to attend to personal matters.
- Board Size Reduction: The number of directors was reduced from seven to six in accordance with the Company's Certificate of Incorporation and Bylaws.
- Committee Appointment: Vincent J. Milano, a current director, was appointed as the new Chairman of the Compensation Committee to replace Dr. Karabelas.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The departure of Dr. Karabelas is attributed to personal matters, and the Company expressed gratitude for his service since the founding of the Company.
Key Facts for Investor Verification
- Confirm the current composition of the Board of Directors and committee assignments following the reduction to six members.
- Verify the effective date of Vincent J. Milano's appointment as Chairman of the Compensation Committee.
- Review subsequent filings to ensure no other undisclosed changes to the Board occurred around this period.